The Trump administration announced a new voluntary program that would lower the out-of-pocket cost Medicare beneficiaries pay for insulin to $35 a month, a move designed to deflate rising anger over prices for medicines and, consequently, give President Trump a lift during an election year.
Assuming drug makers and insurers participate, people with diabetes who enroll in a participating Medicare Part D plan are forecast to save an average of $446 annually, or more than 66% of what they pay today, according to the Centers for Medicare and Medicaid Services. CMS believes that more than 3.3 million Medicare beneficiaries receive one or more of the common forms of insulin.
About the Author Reprints
